Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Measurement properties of the online EuroQol-5D-youth instrument in children and adolescents with type 1 diabetes mellitus, Questionnaire study

  • Mayoral, K.|||0000-0002-7904-4422
  • Rajmil, Luis|||0000-0002-6625-0649
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Garin, Olatz|||0000-0001-6193-0779
  • Pont, Angels|||0000-0002-0602-552X
  • Alonso, Jordi|||0000-0001-8627-9636
  • Bel, Joan|||0000-0002-3577-6322
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Carreras, Gemma|||0000-0002-6718-8381
  • Herrero Espinet, Francisco Javier|||0000-0003-2896-7144
  • Mengibar, Josep Maria
  • Rodriguez Arjona, Maria Dolors|||0000-0002-3548-0564
  • Ravens-Sieberer, Ulrike
  • Raat, Hein
  • Serra-Sutton, Vicky
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Background: The lack of continuity between health-related quality of life (HRQoL) instruments designed for children and adults hinders change analysis with a life course approach. To resolve this gap, EuroQol (EQ) developed the EQ-5D-Youth (EQ-5D-Y), derived from the EQ-5D for adults. Few studies have assessed the metric properties of EQ-5D-Y in children with specific chronic conditions, and none have done so for children with type I diabetes mellitus (T1DM). Objective: This study aimed to evaluate the acceptability, validity, reliability, and responsiveness of the EQ-5D-Y in children and adolescents with T1DM, when administered online. Methods: Participants with T1DM were consecutively recruited from July to December 2014, from a list of potential candidates aged 8-19 years, who attended outpatient pediatric endocrinology units. Before every quarterly routine visit, participants received an email/telephone reminder to complete the online version of two generic HRQoL questionnaires: EQ-5D-Y and KIDSCREEN-27. The EQ-5D-Y measures five dimensions, from which an equally weighted summary score was constructed (range: 0-100). Completion rate and distribution statistics were calculated. Construct validity was evaluated through known group comparisons based on general health, acute diabetic decompensations, mental health, family function, and a multitrait, multimethod matrix between EQ-5D-Y and KIDSCREEN by using Spearman correlations. Construct validity hypotheses were stated a priori. Reliability was assessed with the intraclass correlation coefficient and responsiveness by testing changes over time and calculating the effect size. Reliability and responsiveness were tested among the stable and improved subsamples defined by a KIDSCREEN-10 index change of <4.5 points or ≥4.5 points, respectively, from the first to the fourth visit. Results: Of the 136 participants, 119 (87.5%) responded to the EQ-5D-Y at the last visit. The dimensions that showed higher percentages of participants with problems were "having pain/discomfort" (34.6%) and "worried/sad/unhappy" (28.7%). The mean (SD) of the EQ-5D-Y summary score was 8.5 (10.9), with ceiling and floor effects of 50.7% and 0%, respectively. Statistically significant HRQoL differences between groups defined by their general health (excellent/very good and good/regular/bad) and mental health (Strengths and Difficulties Questionnaire score ≤15 and.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma, Cross-Sectional Study

  • Hernandez, Gimena|||0000-0001-5319-3465
  • Garin, Olatz|||0000-0001-6193-0779
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Pont, Angels|||0000-0002-0602-552X
  • Martí Pastor, Marc|||0000-0001-6189-2178
  • Alonso, Jordi|||0000-0001-8627-9636
  • Van Ganse, Eric|||0000-0002-7463-9187
  • Laforest, Laurent|||0000-0002-3694-7699
  • de Bruin, Marijn|||0000-0003-3100-6803
  • Mayoral, K.|||0000-0002-7904-4422
  • Serra Sutton, Vicky|||0000-0002-7852-175X
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Measurement properties of the EQ-5D-Y administered through a smartphone app in children with asthma, a longitudinal questionnaire study

  • Mayoral, K.|||0000-0002-7904-4422
  • Garin, Olatz|||0000-0001-6193-0779
  • Lizano-Barrantes, Catalina|||0000-0003-1690-631X
  • Pont, Angels|||0000-0002-0602-552X
  • Caballero-Rabasco, M. Araceli|||0000-0002-1080-2192
  • Praena-Crespo, Manuel|||0000-0002-1928-9663
  • Valdesoiro Navarrete, Laura
  • Guerra, Maria Teresa|||0000-0002-0566-1970
  • Castillo Laita, José Antonio|||0000-0002-8355-6199
  • de Mir-Messa, Inés|||0000-0002-1418-4563
  • Tato, Eva|||0000-0001-5034-3093
  • Alonso, Jordi|||0000-0001-8627-9636
  • Serra-Sutton, Vicky
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Asthma impacts children's physical, emotional, and psychosocial Health-Related Quality of Life (HRQL). The EQ-5D-Y is a generic econometric instrument developed to measure HRQL in children. Evaluation of feasibility, validity, reliability, and responsiveness of EQ-5D-Y descriptive system and utility index to allow the assessment of HRQL in children with asthma, aged 8-11 years (self-response version) or under 8 years old (proxy-response version). We used data from baseline to 10 months of follow-up of an observational, prospective study of children with persistent asthma recruited by pediatricians in Spain (2018-2020). HRQL instruments were administered through a smartphone application: ARCA app. The EQ-5D-Y is composed of a 5-dimension descriptive system, a utility index ranging from 1 to - 0.5392, and a general health visual analogue scale (EQ-VAS). The Pediatric Asthma Impact Scale (PROMIS-PAIS) includes 8 items, providing a raw score. Construct validity hypotheses were stated a priori, and evaluated following two approaches, multitrait-multimethod matrix and known groups' comparisons. Reliability and responsiveness subsamples were defined by stability or change in EQ-VAS and the Asthma Control Questionnaire (ACQ), to estimate the intraclass correlation coefficient (ICC) and the magnitude of change over time. The EQ-5D-Y was completed at baseline for 119 children (81 self-responded and 38 through proxy response), with a mean age of 9.1 (1.7) years. Mean (SD) of the EQ-5D-Y utility index was 0.93 (0.11), with ceiling and floor effects of 60.3% and 0%, respectively. Multitrait-multimethod matrix confirmed the associations previously hypothesized for the EQ-5D-Y utility index [moderate with PROMIS-PAIS (0.38) and weak with ACQ (0.28)], and for the EQ-5D-Y dimension "problems doing usual activities" [moderate with the ACQ item (0.35) and weak with the PROMIS-PAIS item (0.17)]. Statistically significant differences were found in the EQ-5D-Y between groups defined by asthma control, reliever inhalers use, and second-hand smoke exposure, with mostly moderate effect sizes (0.45-0.75). The ICC of the EQ-5D-Y utility index in the stable subsamples was high (0.81 and 0.79); and responsiveness subsamples presented a moderate to large magnitude of change (0.68 and 0.78), though without statistical significance. These results support the use of the EQ-5D-Y as a feasible, valid, and reliable instrument for evaluating HRQL in children with persistent asthma. Further studies are needed on the responsiveness of the EQ-5D-Y in this population. The online version contains supplementary material available at 10.1186/s12955-022-01955-5.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Inhaler Technique Questionnaire (InTeQ), Development and Validation of a Brief Patient-Reported Measure

  • Lizano-Barrantes, Catalina|||0000-0003-1690-631X
  • Garin, Olatz|||0000-0001-6193-0779
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Van Ganse, Eric|||0000-0002-7463-9187
  • de Bruin, Marijn|||0000-0003-3100-6803
  • Belhassen, Manon|||0000-0002-9478-5464
  • Mayoral, K.|||0000-0002-7904-4422
  • Pont, Angels|||0000-0002-0602-552X
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
There is a need for instruments designed for patients with asthma to self-report their performance of inhaling steps. We aimed to develop an accessible and easy-to-use patient-reported tool for inhaler technique assessment, which could also serve as a training and monitoring resource for any type of inhaler device, and to evaluate its feasibility, validity, and reliability in adults with asthma. The development was based on literature review and pilot testing with clinicians and patients. The Inhaler Technique Questionnaire (InTeQ) asks about the frequency of performing five steps when using inhalers (on a five-point Likert scale). We analyzed data from adults with persistent asthma (n = 361). We examined the measurement model using Mokken scaling analysis, construct validity by assessing hypotheses on expected discrimination among known groups, and reliability based on internal consistency and reproducibility. Means of the InTeQ items were in the range of 0.23-1.61, and coefficients of homogeneity were above the cutoff point, demonstrating the unidimensionality of the scale. Known groups' global score differences were statistically significant between patients reporting having "Discussed in detail" or having "Not discussed/Only in general" the inhaler technique with their healthcare providers (p = 0.023). The Cronbach's alpha coefficient was 0.716, and the intraclass correlation coefficient was 0.775. The InTeQ is a feasible, valid, and reliable instrument for self-reporting inhaler technique on any type of device.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Montelukast in paediatric asthma and allergic rhinitis, a systematic review and meta-analysis

  • Mayoral, K.|||0000-0002-7904-4422
  • Lizano-Barrantes, Catalina|||0000-0003-1690-631X
  • Zamora, Víctor|||0000-0003-2061-0052
  • Pont, Angels|||0000-0002-0602-552X
  • Miret, Carme|||0000-0001-6154-3998
  • Barrufet, Cristina|||0000-0001-5006-668X
  • Caballero-Rabasco, M. Araceli|||0000-0002-1080-2192
  • Praena-Crespo, Manuel|||0000-0002-1928-9663
  • Bercedo-Sanz, Alberto|||0000-0002-6719-4765
  • Valdesoiro Navarrete, Laura
  • Guerra, Maria Teresa|||0000-0002-0566-1970
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Garin, Olatz|||0000-0001-6193-0779
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo. Protocol registration CRD42020216098 (). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model. Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21-689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (-0.12, -0.20- -0.05 and -0.23, -0.41- -0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44-1.36). The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment. This is the first systematic review focused on the impact of montelukast on children and adolescents with asthma, from the patients' perspective, measured with patient-reported outcome measures (PROMs).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhaler Technique Questionnaire (InTeQ) in pediatric patients with asthma

  • Lizano-Barrantes, Catalina|||0000-0003-1690-631X
  • Garin, Olatz|||0000-0001-6193-0779
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Mayoral, K.|||0000-0002-7904-4422
  • Pont, Angels|||0000-0002-0602-552X
  • Ortiz, Eva María|||0000-0001-6871-5035
  • Caballero-Rabasco, M. Araceli|||0000-0002-1080-2192
  • Praena-Crespo, Manuel|||0000-0002-1928-9663
  • Valdesoiro Navarrete, Laura
  • Guerra, Maria Teresa|||0000-0002-0566-1970
  • Bercedo-Sanz, Alberto|||0000-0002-6719-4765
  • Hernandez, Gimena|||0000-0001-5319-3465
  • Maroni, Camila
  • de Mir-Messa, Inés|||0000-0002-1418-4563
  • Carrasco, María Ángeles
  • Ortega, Marta
  • Servan, Alberto
  • Castillo Laita, José Antonio|||0000-0002-8355-6199
  • Tato, Eva|||0000-0001-5034-3093
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of treatment adherence and inhalation technique on asthma outcomes of pediatric patients, a longitudinal study

  • Lizano-Barrantes, Catalina|||0000-0003-1690-631X
  • Garin, Olatz|||0000-0001-6193-0779
  • Mayoral, K.|||0000-0002-7904-4422
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Pont, Angels|||0000-0002-0602-552X
  • Caballero-Rabasco, M. Araceli|||0000-0002-1080-2192
  • Praena-Crespo, Manuel|||0000-0002-1928-9663
  • Valdesoiro Navarrete, Laura
  • Guerra, Maria Teresa|||0000-0002-0566-1970
  • Bercedo-Sanz, Alberto|||0000-0002-6719-4765
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Introduction: We aimed to evaluate the longitudinal relationships, both at between- and within-person levels, that adherence to inhaled corticosteroid-based maintenance treatment and inhalation technique present with symptom control, exacerbations, and health-related quality of life (HRQoL) in children and adolescents with asthma. Methods: Participants (6-14 years old) from the ARCA (Asthma Research in Children and Adolescents) cohort-a prospective, multicenter, observational study (NCT04480242)-were followed for a period from 6 months to 5 years via computer-assisted telephone interviews and a smartphone application. The Medication Intake Survey-Asthma (MIS-A) was administered to assess the implementation stage of adherence, and the Inhalation Technique Questionnaire (InTeQ) was used to assess the five key steps when using an inhaler. Symptom control was measured with the Asthma Control Questionnaire (ACQ), and HRQL was measured with the EQ-5D and the Patient-Reported Outcomes Measurement Information System-Pediatric Asthma Impact Scale (PROMIS-PAIS). Multilevel longitudinal mixed models were constructed separately with symptom control, exacerbation occurrence, EQ-5D, and PROMIS-PAIS as the dependent variables. Results: Of the 360 participants enrolled, 303 (1,203 interviews) were included in the symptom control and exacerbation analyses, 265 (732) in the EQ-5D, and 215 (617) in the PROMIS-PAIS. Around 60% of participants were male subjects, and most of them underwent maintenance treatment with inhaled corticosteroids plus long-acting β-agonists in a fixed dose (73.3%). Within-person variability was 83.6% for asthma control, 98.6% for exacerbations, 36.4% for EQ-5D, and 49.1% for PROMIS-PAIS. At the within-person level, patients with higher adherence had better symptom control (p = 0.002) and HRQoL over time (p = 0.016). Patients with a better inhalation technique reported worse HRQoL simultaneously (p = 0.012), but they showed better HRQoL in future assessments (p = 0.012). The frequency of reliever use was associated with symptom control (p < 0.001), exacerbation occurrence (p < 0.001), and HRQoL (p = 0.042); and boys were more likely to present better symptom control and HRQoL than girls. Conclusion: Our results confirm longitudinal associations at the within-person level of the two indicators of quality use of inhalers: for adherence to maintenance treatment with symptom control and HRQoL, and for the inhalation technique with HRQoL. Although treatment adherence was shown to be excellent, a third of the participants reported a suboptimal inhalation technique, highlighting the need for actions for improving asthma management of the pediatric population.